Evidence map›Paper›PMID 40438295›Full record

ReviewFrontiers in bioengineering and biotechnology2025

Extracellular vesicles as vital players in drug delivery: a focus on clinical disease treatment.

Tiangang Chen, Dan Chen, Wanting Su, Jianlan Liang, Xiangning Liu, Mingxiang Cai

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. International journal of molecular sciences · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Navigating theNanoscale advances · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Peripheral nerve repair: innovations and future directions.Journal of translational medicine · 2026
    Review
  17. Review
  18. Article
  19. Review
  20. International journal of biological sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tiangang ChenThe First Affiliated Hospital of Jinan University, hospital of Stomatology, School of Stomatology, Clinical Research Platform for Interdiscipline of Stomatology, Jinan University, Guangzhou, China.
Dan ChenThe First Affiliated Hospital of Jinan University, hospital of Stomatology, School of Stomatology, Clinical Research Platform for Interdiscipline of Stomatology, Jinan University, Guangzhou, China.
Wanting SuThe First Affiliated Hospital of Jinan University, hospital of Stomatology, School of Stomatology, Clinical Research Platform for Interdiscipline of Stomatology, Jinan University, Guangzhou, China.
Jianlan LiangThe First Affiliated Hospital of Jinan University, hospital of Stomatology, School of Stomatology, Clinical Research Platform for Interdiscipline of Stomatology, Jinan University, Guangzhou, China.
Xiangning LiuThe First Affiliated Hospital of Jinan University, hospital of Stomatology, School of Stomatology, Clinical Research Platform for Interdiscipline of Stomatology, Jinan University, Guangzhou, China.
Mingxiang CaiThe First Affiliated Hospital of Jinan University, hospital of Stomatology, School of Stomatology, Clinical Research Platform for Interdiscipline of Stomatology, Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs), a diverse population of bilayer lipid-membrane vesicles secreted by cells, have emerged as ideal drug carriers due to their efficient cellular uptake and targeted delivery capabilities. Advancements in medical and bioengineering collaborations have enabled EVs to be engineered for specific marker expression or therapeutic cargo transport, positioning them as a promising modality for treating cancer, neurological disorders, cardiovascular diseases, and beyond. EV-based drug delivery strategies offer distinct advantages, including facilitation of intercellular communication and immune modulation, high biocompatibility and stability, the ability to traverse the blood-brain barrier, and potential synergistic interactions with encapsulated therapeutics to enhance efficacy. This review explores EV isolation and scalable production, emphasizing cost-effective and reproducible manufacturing strategies, cargo-loading methodologies, and therapeutic applications. Additionally, the current landscape of EV-based targeted drug delivery, clinical translation prospects, and prevailing challenges are examined to provide a comprehensive perspective on their potential in drug delivery systems.

Indexed as

clinical disease treatmentdrug delivery systemsextracellular vesiclesseparation and loading technologytargeting

Identifiers

PMID40438295
PMCPMC12116468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.